FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891491597> ?p ?o ?g. }

• W2891491597 endingPage "3090" @default.
• W2891491597 startingPage "3090" @default.
• W2891491597 abstract "3090 Background: CLBS20 is a patient-specific therapeutic vaccine consisting of autologous dendritic cells loaded with antigens from irradiated cells from an autologous tumor cell line. It potentially presents the entire repertoire of unique antigens resulting from nonsynonymous mutations in a patient’s self-renewing melanoma cells. In previously reported single arm and randomized phase 2 trials, CLBS was associated with a 72% 2-year overall survival (OS). In the randomized trial median OS for CLBS20-treated patients was more than twice that for a vaccine consisting of irradiated autologous tumor cells. Mild local injection site reactions was the most common toxicity. Methods: During 2001 to 2011 72 patients with stage 4 or recurrent stage 3 melanoma were treated with CLBS20 (Clinicaltrials.gov NCT00948480 & NCT00436930). Each had a metastatic melanoma lesion surgically resected, from which a tumor cell line was established, cells from which were incubated with autologous dendritic cells to produce the vaccine that was injected s.c. in 500 micrograms sargramostim (GM-CSF) weekly x 3 weeks and monthly x 5 months (mos). This report summarizes long-term survival data for all CLBS20-treated patients from date of first injection. Results: There were 45 men and 27 women. Median age is 52 years (17 to 83). Tumor sources were 37-lymph node, 15-soft tissue, 20-viscera. Prior therapies included 72-surgery, 41-chemotherapy, 33-Interleukin-2, 30-interferon alpha, 24-GM-CSF, 19-radiation therapy (RT), and 15-RT for brain metastases. All 33 surviving patients were followed 5 years; none were lost to follow up. Median OS is 45.6 mos; 5-year OS is 46%. Median progression free survival (PFS) is 4.4 mos, 5-year PFS is 19%. The 20 patients with recurrent stage 3, have a 70% 5-year OS, median PFS 19.8 mos, and 35% 5-year PFS. For the 52 patients with stage 4, median OS is 41.0 mos, 5-year OS is 36%, and median PFS is 3.8 mos. One patient with refractory progressive measurable disease experienced a delayed complete response that was ongoing at 5 years. Conclusions: CLBS20 is associated with encouraging 5-year overall survival. Because of its unique mechanism of action and absence of toxicity, it should be evaluated further in similar patients. Clinical trial information: NCT00948480. Clinical trial information: NCT00436930." @default.
• W2891491597 created "2018-09-27" @default.
• W2891491597 creator A5013377891 @default.
• W2891491597 creator A5063296555 @default.
• W2891491597 date "2016-05-20" @default.
• W2891491597 modified "2023-09-25" @default.
• W2891491597 title "5-year follow up for 72 metastatic melanoma patients treated with eltrapuldencel-T (CLBS20) vaccine." @default.
• W2891491597 doi "https://doi.org/10.1200/jco.2016.34.15_suppl.3090" @default.
• W2891491597 hasPublicationYear "2016" @default.
• W2891491597 type Work @default.
• W2891491597 sameAs 2891491597 @default.
• W2891491597 citedByCount "0" @default.
• W2891491597 crossrefType "journal-article" @default.
• W2891491597 hasAuthorship W2891491597A5013377891 @default.
• W2891491597 hasAuthorship W2891491597A5063296555 @default.
• W2891491597 hasConcept C121608353 @default.
• W2891491597 hasConcept C126322002 @default.
• W2891491597 hasConcept C141071460 @default.
• W2891491597 hasConcept C143998085 @default.
• W2891491597 hasConcept C147483822 @default.
• W2891491597 hasConcept C203014093 @default.
• W2891491597 hasConcept C2776624504 @default.
• W2891491597 hasConcept C2777658100 @default.
• W2891491597 hasConcept C2777701055 @default.
• W2891491597 hasConcept C2780849966 @default.
• W2891491597 hasConcept C502942594 @default.
• W2891491597 hasConcept C71924100 @default.
• W2891491597 hasConcept C90924648 @default.
• W2891491597 hasConceptScore W2891491597C121608353 @default.
• W2891491597 hasConceptScore W2891491597C126322002 @default.
• W2891491597 hasConceptScore W2891491597C141071460 @default.
• W2891491597 hasConceptScore W2891491597C143998085 @default.
• W2891491597 hasConceptScore W2891491597C147483822 @default.
• W2891491597 hasConceptScore W2891491597C203014093 @default.
• W2891491597 hasConceptScore W2891491597C2776624504 @default.
• W2891491597 hasConceptScore W2891491597C2777658100 @default.
• W2891491597 hasConceptScore W2891491597C2777701055 @default.
• W2891491597 hasConceptScore W2891491597C2780849966 @default.
• W2891491597 hasConceptScore W2891491597C502942594 @default.
• W2891491597 hasConceptScore W2891491597C71924100 @default.
• W2891491597 hasConceptScore W2891491597C90924648 @default.
• W2891491597 hasIssue "15_suppl" @default.
• W2891491597 hasLocation W28914915971 @default.
• W2891491597 hasOpenAccess W2891491597 @default.
• W2891491597 hasPrimaryLocation W28914915971 @default.
• W2891491597 hasRelatedWork W1981522720 @default.
• W2891491597 hasRelatedWork W2002120878 @default.
• W2891491597 hasRelatedWork W2003938723 @default.
• W2891491597 hasRelatedWork W2047967234 @default.
• W2891491597 hasRelatedWork W2096555825 @default.
• W2891491597 hasRelatedWork W2328036837 @default.
• W2891491597 hasRelatedWork W2412950296 @default.
• W2891491597 hasRelatedWork W2439875401 @default.
• W2891491597 hasRelatedWork W281395926 @default.
• W2891491597 hasRelatedWork W340134614 @default.
• W2891491597 hasVolume "34" @default.
• W2891491597 isParatext "false" @default.
• W2891491597 isRetracted "false" @default.
• W2891491597 magId "2891491597" @default.
• W2891491597 workType "article" @default.